A Phase 4 interventional study of Sodium hyaluronate 0.1%/chondroitin sulfate 0.18% and Sodium hyaluronate 0.15% in Dry Eye, sponsored by Laboratorios Sophia S.A de C.V.. Completed at 1 site in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-20.
Sponsored by Laboratorios Sophia S.A de C.V. · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing Hyaluronic Acid in Dry Eye Syndromes — 3 open to participants now, 3 under way, none of them phase 3. Hyaluronic Acid · Dry Eye Syndromes.
Among the 18 studies testing Hyaluronic Acid in Dry Eye Syndromes, this one is the 3rd largest by enrollment, is one of 3 that started in 2021, is one of 5 in phase 4, and was the 13th registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →3 of the 18 studies testing Hyaluronic Acid in Dry Eye Syndromes are open now, in 1 country. Recruiting first, the newest first:
Jin Yang · Sites in China
Beijing Tongren Hospital · Sites in China
Ages 18–65
He Eye Hospital
Ages 18–60 · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 2 · Phase 4 5
First in 2006; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 182 is above the median of 60 across 1,131 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 88 across the 18 interventional studies. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 18 have an industry lead sponsor. The 10 most frequent:
Laboratorios Sophia S.A de C.V. is the lead sponsor of 45 studies on the registry; 5 are open to participants now.
13 studies in Dry Eye Syndromes by Laboratorios Sophia S.A de C.V.: 2 open now, 2 under way, none of them phase 3. Of 11 finished, 10 (91%) have results posted.
Among the 13 studies in Dry Eye Syndromes by Laboratorios Sophia S.A de C.V., this one is the 3rd largest by enrollment, is the only one that started in 2021, is one of 2 in phase 4, and was the 9th registered.
Laboratorios Sophia S.A de C.V.’s Dry Eye Syndromes studies by the year they started, since 2011.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing Hyaluronic Acid in Dry Eye Syndromes, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Laboratorios Sophia S.A de C.V.’s 13 in Dry Eye Syndromes:
This tab as a report to print or save as PDF → With an account.
Phase IV, non inferiority, controlled, open, multicenter clinical study to compare the efficacy of the Ophthalmic Solution Humylub Ofteno® PF against Hyabak® and Lagricel Ofteno® PF applied quater in die (QID) for 30 days in patients with mild to moderate dry eye disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Presenting a mild to moderate dry eye disease diagnosis, defined as:
OSDI score ≥ 13, plus one of the following:
Exclusion Criteria:
Diagnosis of any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Humylub Ofteno® PF (sodium hyaluronate 0.1%/chondroitin sulfate 0.18%) ophthalmic solution applied QID for 30 days.
Drug: Sodium hyaluronate 0.1%/chondroitin sulfate 0.18%
Hyabak® PF (sodium hyaluronate 0.15%) ophthalmic solution applied QID for 30 days.
Drug: Sodium hyaluronate 0.15%
Lagricel Ofteno® PF (sodium hyaluronate 0.4%) ophthalmic solution applied QID for 30 days.
Drug: Sodium hyaluronate 0.4%
Drug page: Hyaluronic Acid
Application of one drop of Humylub Ofteno® PF (Sodium hyaluronate 0.1%/chondroitin sulfate 0.18%) QID in both eyes (OU) during 30 days.
Also known as: Humylub Ofteno® PF, PRO-087
Application of one drop of Hyabak® PF (Sodium hyaluronate 0.15%) QID in OU during 30 days.
Also known as: Hyabak® PF
Application of one drop of Lagricel Ofteno® PF (Sodium Hyaluronate 0.4%) QID in OU during 30 days.
Also known as: Lagricel Ofteno® PF, PRO-037
Change in Ocular Surface Disease Index (OSDI)
OSDI is a 12-item questionnaire used to evaluate symptoms associated with dry eye disease, as well as classify their severity. According the obtained score, categories are as follows: normal (0-12 points), mild (13-22 points), moderate (23-32 points), or severe (33-100 points). A higher score is a worse outcome. • This outcome measure considered the Per Protocol (PP) population.
Time frame: Days: 0 (± 2) (eligibility visit), 17 - 19 (± 1) (first follow-up visit), and 31 - 33 (± 1) (final visit).
Noninvasive Keratograph Break-up Time (NIKBUT)
This evaluation will be performed through an Oculus Keratograph 5M, and the parameter "first break-up time" will be recorded as NIKBUT. A lower value is a worse outcome. This outcome measure considered the Per Protocol (PP) population.
Time frame: Days: 0 - 2 (baseline visit),17 - 19 (± 1) (first follow-up visit), and 31 - 33 (± 1) (final visit).
Change of Conjunctival and Corneal Staining With Lissamine Green
The change in proportion of participant's abscence of conjunctival and corneal staining with lissamine green will be analyzed. The evaluation will take place after applying the lissamine green stain on the ocular surface and evaluating the resulting staining pattern. This will be measured through the Oxford scale which includes 6 grades: Absent (0), Minimal (I), Mild (II), Moderate (III), Marked (IV), Severe (V). This outcome measure considered the Per Protocol (PP) population.
Time frame: Days: 0 (eligibility visit), 17 - 19 (± 1) (first follow-up visit), and 31 - 33 (± 1) (final visit).
Change of Conjunctival and Corneal Staining With Fluorescein
The change in proportion of participant's abscence of conjunctival and corneal staining with fluorescein will be analyzed. The evaluation will take place after applying the fluorescein stain on the ocular surface and evaluating the resulting staining pattern. This will be measured through the Oxford scale which includes 6 grades: Absent (0), Minimal (I), Mild (II), Moderate (III), Marked (IV), Severe (V). This outcome measure considered the Per Protocol (PP) population.
Time frame: Days: 0 (eligibility visit), 17 - 19 (± 1) (first follow-up visit), and 31 - 33 (± 1) (final visit).
Change in Conjunctival Hyperemia
The change in proportion of participant's score will be analyzed. Rate of conjunctival hyperemia will be evaluated through the Efron scale which includes 5 grades: Normal (0), Very Mild (I), Mild (II), Moderate (3), and Severe (4). This outcome measure considered the Per Protocol (PP) population.
Time frame: Days: 0 (eligibility visit), 17 - 19 (± 1) (first follow-up visit), and 31 - 33 (± 1) (final visit).
Incidence of Related Non Expected Adverse Events
Number of related non expected adverse events observed per group. This outcome measure considered the Intention-To-Treat (ITT) population, all participants who were randomized and exposed to treatment, regardless of whether they finished the study.
Time frame: Days: 0 (eligibility visit), 0 - 2 (baseline visit),17 - 19 (± 1) (first follow-up visit), 31 - 33 (± 1) (final visit), and 38 - 40 (± 1) (safety call).
Change in Best Corrected Visual Acuity (BCVA)
With the patient's best possible refractive correction, visual acuity will be evaluated through the Snellen chart. Its notation (decimal) is described as the distance from the chart at which the test is performed, divided by the distance at which a letter equals vertically 5 minutes of arc. Visual acuity (VA) is a test of visual function. It will be evaluated with the Snellen chart. The Snellen chart is the standard tool used to evaluate visual acuity. It was located in a place with adequate lighting, natural or artificial and at a distance of 3 meters from the subject to be evaluated. The contralateral eye to which it will be evaluated is covered, then the examiner detects until the line can clearly see the letters given he or she a score, the normal score for a VA is 20/20. This score can be expressed in fraction (i.e. 20/20) decimal (i.e. 1.0), or LogMAR (i.e. 0) formats. In this study, VA is expressed in decimal format. In decimal format, a lower number is a worse outcome.
Time frame: Days: 0 (eligibility visit), 17 - 19 (± 1) (first follow-up visit), and 31 - 33 (± 1) (final visit).
Change in Incidence of Chemosis
Chemosis will be evaluated as present (if conjunctiva separates from the sclera in ≥ 1/3 of the palpebral opening area or if it exceeds the eyelid's gray line) or absent per subject. This outcome measure considered the Intention-To-Treat (ITT) population, all participants who were randomized and exposed to treatment, regardless of whether they finished the study.
Time frame: Days: 0 (eligibility visit), 17 - 19 (± 1) (first follow-up visit), and 31 - 33 (± 1) (final visit).
| Milestone | Arm 1; Humylub Ofteno® PF | Arm 2; Hyabak® | Arm 3; Lagricel Ofteno® PF |
|---|---|---|---|
| Started | 61 | 61 | 60 |
| Completed | 56 | 56 | 52 |
| Not completed | 5 | 5 | 8 |
| Withdrew: Adverse event | 1 | 2 | 1 |
| Withdrew: Lost to follow-up | 2 | 1 | 4 |
| Withdrew: Protocol violation | 2 | 2 | 3 |
OSDI is a 12-item questionnaire used to evaluate symptoms associated with dry eye disease, as well as classify their severity. According the obtained score, categories are as follows: normal (0-12 points), mild (13-22 points), moderate (23-32 points), or severe (33-100 points). A higher score is a worse outcome. • This outcome measure considered the Per Protocol (PP) population.
| score on a scale | Arm 1; Humylub Ofteno® PF | Arm 2; Hyabak® | Arm 3; Lagricel Ofteno® PF |
|---|---|---|---|
| Elegibility visit | 26.4 ± 5.1 | 26.3 ± 5.8 | 26.6 ± 4.9 |
| First follow-up visit | 16.4 ± 8.3 | 14.0 ± 10.4 | 15.2 ± 8.3 |
| Final visit | 11.2 ± 9.4 | 8.8 ± 7.5 | 10.7 ± 9.0 |
This evaluation will be performed through an Oculus Keratograph 5M, and the parameter "first break-up time" will be recorded as NIKBUT. A lower value is a worse outcome. This outcome measure considered the Per Protocol (PP) population.
| seconds | Arm 1; Humylub Ofteno® PF | Arm 2; Hyabak® | Arm 3; Lagricel Ofteno® PF |
|---|---|---|---|
| Baseline visit | 6.8 ± 3.9 | 5.2 ± 3.0 | 7.1 ± 4.3 |
| First follow-up visit | 7.3 ± 4.8 | 6.9 ± 4.8 | 7.7 ± 4.9 |
| Final visit | 8.7 ± 5.3 | 7.8 ± 4.9 | 7.1 ± 3.9 |
The change in proportion of participant's abscence of conjunctival and corneal staining with lissamine green will be analyzed. The evaluation will take place after applying the lissamine green stain on the ocular surface and evaluating the resulting staining pattern. This will be measured through the Oxford scale which includes 6 grades: Absent (0), Minimal (I), Mild (II), Moderate (III), Marked (IV), Severe (V). This outcome measure considered the Per Protocol (PP) population.
| Participants | Arm 1; Humylub Ofteno® PF | Arm 2; Hyabak® | Arm 3; Lagricel Ofteno® PF |
|---|---|---|---|
| Eligibility visit — 0 | 20 | 23 | 16 |
| Eligibility visit — I | 21 | 22 | 24 |
| Eligibility visit — II | 3 | 4 | 0 |
| Eligibility visit — III | 2 | 0 | 0 |
| Eligibility visit — IV | 0 | 0 | 0 |
| First follow-up visit — 0 | 25 | 28 | 25 |
| First follow-up visit — I | 16 | 19 | 12 |
| First follow-up visit — II | 4 | 1 | 3 |
| First follow-up visit — III | 0 | 1 | 0 |
| First follow-up visit — IV | 1 | 0 | 0 |
| Final visit — 0 | 33 | 32 | 23 |
| Final visit — I | 12 | 15 | 17 |
| Final visit — II | 1 | 2 | 0 |
| Final visit — III | 0 | 0 | 0 |
| Final visit — IV | 0 | 0 | 0 |
The change in proportion of participant's abscence of conjunctival and corneal staining with fluorescein will be analyzed. The evaluation will take place after applying the fluorescein stain on the ocular surface and evaluating the resulting staining pattern. This will be measured through the Oxford scale which includes 6 grades: Absent (0), Minimal (I), Mild (II), Moderate (III), Marked (IV), Severe (V). This outcome measure considered the Per Protocol (PP) population.
| Participants | Arm 1; Humylub Ofteno® PF | Arm 2; Hyabak® | Arm 3; Lagricel Ofteno® PF |
|---|---|---|---|
| Elegibility visit — 0 | 19 | 20 | 16 |
| Elegibility visit — I | 19 | 27 | 20 |
| Elegibility visit — II | 7 | 2 | 4 |
| Elegibility visit — III | 1 | 0 | 0 |
| First follow-up visit — 0 | 31 | 23 | 25 |
| First follow-up visit — I | 12 | 22 | 14 |
| First follow-up visit — II | 3 | 4 | 1 |
| First follow-up visit — III | 0 | 0 | 0 |
| Final visit — 0 | 36 | 34 | 24 |
| Final visit — I | 10 | 15 | 14 |
| Final visit — II | 0 | 0 | 2 |
| Final visit — III | 0 | 0 | 0 |
The change in proportion of participant's score will be analyzed. Rate of conjunctival hyperemia will be evaluated through the Efron scale which includes 5 grades: Normal (0), Very Mild (I), Mild (II), Moderate (3), and Severe (4). This outcome measure considered the Per Protocol (PP) population.
| Participants | Arm 1; Humylub Ofteno® PF | Arm 2; Hyabak® | Arm 3; Lagricel Ofteno® PF |
|---|---|---|---|
| Elegibility visit — Normal | 21 | 15 | 14 |
| Elegibility visit — Very Mild | 14 | 17 | 12 |
| Elegibility visit — Mild | 9 | 15 | 11 |
| Elegibility visit — Moderate | 2 | 2 | 3 |
| Elegibility visit — Severe | 0 | 0 | 0 |
| First follow-up visit — Normal | 23 | 22 | 22 |
| First follow-up visit — Very Mild | 17 | 22 | 14 |
| First follow-up visit — Mild | 6 | 5 | 4 |
| First follow-up visit — Moderate | 0 | 0 | 0 |
| First follow-up visit — Severe | 0 | 0 | 0 |
| Final visit — Normal | 32 | 33 | 27 |
| Final visit — Very Mild | 11 | 14 | 13 |
| Final visit — Mild | 3 | 2 | 0 |
| Final visit — Moderate | 0 | 0 | 0 |
| Final visit — Severe | 0 | 0 | 0 |
Number of related non expected adverse events observed per group. This outcome measure considered the Intention-To-Treat (ITT) population, all participants who were randomized and exposed to treatment, regardless of whether they finished the study.
| adverse events | Arm 1; Humylub Ofteno® PF | Arm 2; Hyabak® | Arm 3; Lagricel Ofteno® PF |
|---|---|---|---|
| Incidence of Related Non Expected Adverse Events | 5 | 5 | 10 |
With the patient's best possible refractive correction, visual acuity will be evaluated through the Snellen chart. Its notation (decimal) is described as the distance from the chart at which the test is performed, divided by the distance at which a letter equals vertically 5 minutes of arc. Visual acuity (VA) is a test of visual function. It will be evaluated with the Snellen chart. The Snellen chart is the standard tool used to evaluate visual acuity. It was located in a place with adequate lighting, natural or artificial and at a distance of 3 meters from the subject to be evaluated. The contralateral eye to which it will be evaluated is covered, then the examiner detects until the line can clearly see the letters given he or she a score, the normal score for a VA is 20/20. This score can be expressed in fraction (i.e. 20/20) decimal (i.e. 1.0), or LogMAR (i.e. 0) formats. In this study, VA is expressed in decimal format. In decimal format, a lower number is a worse outcome.
| decimal | Arm 1; Humylub Ofteno® PF | Arm 2; Hyabak® | Arm 3; Lagricel Ofteno® PF |
|---|---|---|---|
| Elegibility visit | 0.97 ± 0.18 | 0.95 ± 0.21 | 0.94 ± 0.20 |
| First follow-up visit | 0.99 ± 0.17 | 0.98 ± 0.26 | 0.96 ± 0.22 |
| Final visit | 0.99 ± 0.2 | 0.96 ± 0.18 | 0.96 ± 0.22 |
Chemosis will be evaluated as present (if conjunctiva separates from the sclera in ≥ 1/3 of the palpebral opening area or if it exceeds the eyelid's gray line) or absent per subject. This outcome measure considered the Intention-To-Treat (ITT) population, all participants who were randomized and exposed to treatment, regardless of whether they finished the study.
| Participants | Arm 1; Humylub Ofteno® PF | Arm 2; Hyabak® | Arm 3; Lagricel Ofteno® PF |
|---|---|---|---|
| Elegibility visit | 0 | 0 | 0 |
| First follow-up visit | 0 | 0 | 0 |
| Final visit | 0 | 0 | 0 |
Collected over Adverse event data was recollected starting from the elegibility visit (day 0) until the security call (day 38 - 40) done at the end of the study. In this study, AE were collected during of 1 year, 5 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1; Humylub Ofteno® PF | 0/61 (0%) | 1/61 (1.6%) | 40/61 (65.6%) |
| Arm 2; Hyabak® | 0/61 (0%) | 0/61 (0%) | 39/61 (63.9%) |
| Arm 3; Lagricel Ofteno® PF | 0/60 (0%) | 0/60 (0%) | 43/60 (71.7%) |
| Event | Arm 1; Humylub Ofteno® PF | Arm 2; Hyabak® | Arm 3; Lagricel Ofteno® PF |
|---|---|---|---|
| Convulsive CrisisNervous system disorders | 1/61 | 0/61 | 0/60 |
| Event | Arm 1; Humylub Ofteno® PF | Arm 2; Hyabak® | Arm 3; Lagricel Ofteno® PF |
|---|---|---|---|
| Ocular burningEye disorders | 27/61 | 29/61 | 30/60 |
| PruritusEye disorders | 11/61 | 5/61 | 15/60 |
| Foreign body sensation in the eyeEye disorders | 5/61 | 2/61 | 9/60 |
| HeadacheNervous system disorders | 0/61 | 0/61 | 3/60 |
| EyestrainEye disorders | 2/61 | 0/61 | 2/60 |
| TearingEye disorders | 2/61 | 1/61 | 2/60 |
| Ocular hyperemiaEye disorders | 1/61 | 2/61 | 0/60 |
The manifested adverse events during the conduction of this trial were obtained during trial visits and reported in the electronic CRF, where the clinical team of the center included the information from source documents. These were previously checked by the monitor team, pharmacovigilance specialist, and the medical specialist part of the sponsor's crew to verify concordance with what was stipulated in the protocol.
| Age, Categorical(Participants) | Arm 1; Humylub Ofteno® PF | Arm 2; Hyabak® | Arm 3; Lagricel Ofteno® PF | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 61 | 61 | 60 | 182 |
| >=65 years | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Arm 1; Humylub Ofteno® PF | Arm 2; Hyabak® | Arm 3; Lagricel Ofteno® PF | Total |
|---|---|---|---|---|
| Mean | 29.5 ± 11 | 31.7 ± 11.7 | 31.4 ± 10.2 | 30.9 ± 11 |
| Sex: Female, Male(Participants) | Arm 1; Humylub Ofteno® PF | Arm 2; Hyabak® | Arm 3; Lagricel Ofteno® PF | Total |
|---|---|---|---|---|
| Female | 33 | 33 | 36 | 102 |
| Male | 28 | 28 | 24 | 80 |
| Ethnicity (NIH/OMB)(Participants) | Arm 1; Humylub Ofteno® PF | Arm 2; Hyabak® | Arm 3; Lagricel Ofteno® PF | Total |
|---|---|---|---|---|
| Hispanic or Latino | 61 | 61 | 60 | 182 |
| Not Hispanic or Latino | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Arm 1; Humylub Ofteno® PF | Arm 2; Hyabak® | Arm 3; Lagricel Ofteno® PF | Total |
|---|---|---|---|---|
| Mexico | 61 | 61 | 60 | 182 |
| Conjunctival hyperemia(Participants) | Arm 1; Humylub Ofteno® PF | Arm 2; Hyabak® | Arm 3; Lagricel Ofteno® PF | Total |
|---|---|---|---|---|
| Count of participants | 24 | 19 | 16 | 59 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2021 to primary completion in May 2023, 17 months.
Results were first posted in Jan 2026, 2 years 7 months after primary completion.
Of 28 industry-sponsored phase 4 interventional studies under Dry Eye Syndromes, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 15. This study's 17 months is above that.
Counting every sponsor, half of 112 studies reached it within 12 months; a quarter within 5 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hyaluronic Acid
Laboratorios Sophia S.A de C.V. →